Clinical Trials Logo

Suicidal Ideation clinical trials

View clinical trials related to Suicidal Ideation.

Filter by:

NCT ID: NCT05580757 Completed - Suicide Clinical Trials

Pharmacists as Gate Keepers in Suicide Prevention: Needs of Pharmacists

Start date: September 2, 2022
Phase:
Study type: Observational

This study aims to examine the opinions and needs of pharmacists and pharmaceutical technical assistants (FTA) concerning their role as gatekeepers in suicide prevention. The primary objective is to map the experiences and needs of (public) pharmacists and FTA with regard to suicide prevention. The secondary objective is to be able to develop more targeted tools, interventions or trainings based on the results of the needs assessment in order to facilitate the role of (public) pharmacists and FTA as gatekeepers in suicide prevention.

NCT ID: NCT05555927 Recruiting - Suicidal Ideation Clinical Trials

Adjunctive Duration-doubled tDCS for the Treatment of Depressive Patients With Suicidal Ideation

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

In this double-blinded, randomized, sham-controlled trial, the investigators aim to determine the acute effectiveness of duration-doubled tDCS on suicidal ideation in patients with MDD. In addition to the their usual treatment, participants will be randomly assigned to receive either 10 weekday sessions of active (2 mA) or sham tDCS as an adjunctive treatment, with the anode over the left DLPFC and the cathode over the right DLPFC. The investigators will regularly assess suicidal ideation, depression severity and functional impact using the BSI, HAMD-17, MADRS, ODQ, YMRS, ASRM, CGI and SDS throughout the trial. The investigators will assess cognitive changes using WCST and SCWT. The investigators will also regularly assess treatment-related side effects using validated scales.

NCT ID: NCT05541900 Completed - Suicidal Ideation Clinical Trials

A Conditioning Paradigm to Increase Affinity for Sacredness of Life

Start date: May 11, 2022
Phase: N/A
Study type: Interventional

Suicide-related experiences affect millions of people every year in the United States. Through decades of research, interventions targeting these experiences have developed with varied empirical support. Many of these treatments require regular attendance to in-person sessions with a trained behavioral health professional. Limitations of in-person services have led to the development of digital-based interventions, such as Therapeutic Evaluative Conditioning (TEC). TEC is based in evaluative conditioning principles and is a brief (1-2 minutes) digital intervention designed to increase aversion to self-injurious behaviors while decreasing aversion to the self through a match game-like task. Initial assessment of the intervention demonstrated promising results although treatment effects did not remain over time. Separately, sanctification, or the process through which aspects of life are perceived as having divine character and significance, can come from a theistic or nontheistic background and does not require a belief in a God or higher power to be experienced. When something is discovered as sacred, that sacredness becomes a priority for the individual, initiating motivation to conserve what is viewed as sacred. The primary aim of the current study is to develop and test the effectiveness of an adapted version of TEC designed to increase affinity for sacredness of life and increase the connection to life as mechanisms for decreasing suicide-related experiences. Results will provide insight into the perception of sacredness of life as a potential treatment target and are foundational work in a novel approach to address the public health priority of prevention and treatment of suicide-related experiences.

NCT ID: NCT05539352 Not yet recruiting - Suicidal Ideation Clinical Trials

Improving Caregivers' Ability to Manage Life Stress

Start date: June 3, 2024
Phase: N/A
Study type: Interventional

The COVID-19 pandemic has led to increased caregiving demands for caregivers of Veterans with dementia. Dementia caregivers are particularly at-risk for depression and anxiety, known risk factors for increased suicidality. Emerging research also suggests that dementia caregivers are experiencing greater suicidality during COVID-19 at a time when VHA is also devoting increased efforts toward caregiver health and support services. Aims are to determine the feasibility and acceptability of video-delivered Problem-Solving Therapy for reducing suicide risk in caregivers of Veterans with dementia.

NCT ID: NCT05537376 Recruiting - Suicidal Ideation Clinical Trials

A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness

Start date: September 12, 2023
Phase: N/A
Study type: Interventional

Suicide is a major public health concern, particularly among Veterans with serious mental illness (SMI, i.e., psychotic disorders or bipolar disorders). Wellness Recovery Action Plan (WRAP) is a well-established evidence-based practice for those with SMI that centers on identifying warning signs of mental illness, developing wellness tools for functional independence, planning for day-to-day effective living within one's community, and building an action plan to create a valued life worth living. This proposed study will refine and pilot SUicide Prevention by Peers Offering Recovery Tactics (SUPPORT), a novel integrated recovery program that is an adaptation of peer-delivered WRAP for Veterans with SMI. In SUPPORT, a Peer Specialist leads a Veteran at increased risk for suicide through recovery planning that is tailored to the Veteran's suicidal experiences with cognitive learning strategies to enhance safety plan recall and improve functioning.

NCT ID: NCT05485701 Recruiting - Depression Clinical Trials

Perinatal Mental Health Study (PMHS) India

PMHS
Start date: September 1, 2022
Phase:
Study type: Observational

The purpose of this observational study is to improve understanding of mental disorders among perinatal women in India.

NCT ID: NCT05468840 Not yet recruiting - Suicidal Ideation Clinical Trials

Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation

Start date: June 2023
Phase: Phase 3
Study type: Interventional

Approximately 20% of Canadian adolescents experience thoughts of suicide, or suicidal ideation (SI), and suicide is the second leading cause of death among Canadians aged 15-19 years. The emergency department at CHEO sees approximately four patients per day with SI. Even though this is a medical emergency, there are no fast-acting treatments available. Ketamine is a medication that is commonly used to safely sedate children who require painful procedures in the emergency department. For nearly ten years, intravenous ketamine has also been shown to rapidly reduce SI in adults. However, ketamine as a treatment for SI has never been studied in adolescents. The primary study objective is to pilot a clinical trial that investigates intravenous ketamine to emergently treat SI in adolescents. If intravenous ketamine can relieve symptoms of SI for youth, this would have tremendous effects on patients and would dramatically change how physicians treat adolescent mental health emergencies. If ketamine is effective for several weeks, as it is in adults, it will help temporize patients until they receive more long-term psychiatric care. At the system level, it has the potential to reduce emergency visits and lengthy admissions. The investigators feel that the results of this study will be generalizable to pediatric centres across Canada and beyond.

NCT ID: NCT05458830 Completed - Suicidal Ideation Clinical Trials

Breaking Down Barriers to a Suicide Prevention Helpline

Start date: October 7, 2022
Phase: N/A
Study type: Interventional

Every month, around four thousand people fill in the anonymous self-test for suicidal thoughts on the website of the Dutch suicide prevention helpline 113 Suicide Prevention. The self-test includes the Suicidal Ideation Attributes Scale (SIDAS) and informs people about the severity of their suicidal thoughts. The vast majority (70%) of people who complete the test score higher than the cut-off point (≥ 21) for severe suicidal thoughts. Despite this, only around 10% of test-takers navigate to the webpage about contacting the helpline. In this study the investigators test an intervention that aims to reduce barriers to contacting the helpline via chat or phone. People with severe suicidal thoughts and little motivation to contact the helpline will be randomly allocated either to a brief Barrier Reduction Intervention (BRI) or care as usual, a plain advisory text. The aim of our study is two-fold: (i) to measure the effectiveness of a brief barrier reduction intervention (BRI) in the self-test motivating people with severe suicidal thoughts to contact the helpline, and (ii) to specifically evaluate the effectiveness of the intervention in increasing service utilisation by high-risk groups for suicide such as men and people of middle age.

NCT ID: NCT05453864 Not yet recruiting - Suicidal Ideation Clinical Trials

CMAP Plus Trauma-focused Cognitive Behavior Therapy for Suicidal Ideation Among Burn Survivors

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The study aims to determine whether CMAP Plus TFBCT is feasible and acceptable for burn survivors with suicidal ideations. To identify any barriers to the recruitment of participants. To determine initial data for the primary outcome measure to perform a sample size calculation for a larger trial.

NCT ID: NCT05430022 Completed - Depression Clinical Trials

Group Depression Treatment for Autistic Youth

Start date: July 21, 2021
Phase: N/A
Study type: Interventional

Higher rates of depression are reported by autistic adolescents as compared to their non-autistic peers, which is problematic given adverse outcomes (e.g., negative self-esteem, lower academic performance) that are associated with depression. Despite the alarming rates of depression in autistic youth and associated safety concerns, few treatments have been developed. In this study, we investigate the feasibility, acceptability, and preliminary efficacy of an autism-adapted group cognitive-behavioral treatment for autistic adolescents (11-17 years old; middle and high school) in a pilot, nonrandomized trial. Specifically, we aim to increase adolescents' perception and understanding of self, including autistic identity, in order to treat depression. Intervention design and implementation were guided by autistic self-advocates and parents.